WALTHAM, Mass .– (BUSINESS WIRE) – December 2, 2021–
AlloVir (Nasdaq: ALVR), an advanced clinical cell therapy company, announced today that it will host a virtual investor event on Monday, December 13, 2021 at 8:00 a.m. EST. The event will include an AlloVir company update and a review of initial data from a Phase 2 study of posoleucel for multi-virus prevention that will be presented at the American Society of Hematology (ASH) Annual Meeting on Saturday, December 11, 2021. Posoleucel is an experimental virus-specific T cell therapy under evaluation for the prevention of six potentially fatal viruses that commonly affect recipients of allogeneic hematopoietic stem cell transplants (allo-HSCT) – adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6 and JC virus.
The virtual event will feature Diana Brainard, MD, CEO of AlloVir, who will provide an update on the company’s key programs, with a focus on posoleucel. Sanjeet Dadwal, MD, Division Chief of Infectious Diseases and Professor of Medicine, City of Hope, will discuss the risks associated with viral infection in allo-HSCT recipients, the potential impact of preventive treatment and the data initials of the posoleucel multivirus prevention study.
A live audio webcast of the presentation will be available in the Investors and Press section of the AlloVir website at https://ir.allovir.com/events-and-presentations. An archived replay of the presentation will be available on the website for 30 days following the event.
AlloVir is a leading clinical advanced cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms harness ready-to-use, allogeneic, virus-specific T cells for patients with T cell deficiencies who are exposed to the deadly consequences of viral diseases. AlloVir’s technology and manufacturing process enables the treatment and prevention of a range of devastating viruses with every single allogeneic cell therapy . The company is advancing several mid-stage and advanced clinical trials in its product portfolio. For more information visit www.allovir.com or follow us on Twitter Where LinkedIn.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the development of AlloVir and the regulatory status of our product candidates, the planned conduct of its preclinical studies, and clinical trials and its prospects for success in these studies and trials, as well as its strategy, business plans and direction. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimate “,” predict “,” project “,” potential “,” continue “,” target “and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All forward-looking statements contained in this press release are based on the current expectations and beliefs of management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to occur. differ materially from those expressed or implied by any forward-looking statement. the forward-looking statements contained in this press release, including, without limitation, those relating to AlloVir’s financial results, the timing of the launch and success of AlloVir’s clinical trials on its product candidates, if and when, where applicable, AlloVir product candidates will receive approval from the United States Food and Drug Administration, or the FDA, or other foreign regulatory authorities, competition from other biopharmaceutical companies, the impact of the COVID-19 pandemic to AlloVir’s product development plans, supply chain and business operations and other risks identified in AlloVir Deposits with the SEC. AlloVir cautions you not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made. AlloVir disclaims any obligation to publicly update or revise such statements to reflect any change in expectations or in the events, conditions or circumstances on which such statements may be based, or which may affect the likelihood that actual results will differ from those set forth in forward-looking statements. All forward-looking statements contained in this press release represent the views of AlloVir only as of the date hereof and should not be taken as representing its views as of any later date.
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL HEALTH CLINICAL TRIALS
Copyright Business Wire 2021.
PUB: 12/02/2021 4:05 PM / DISC: 12/02/2021 4:06 PM
Copyright Business Wire 2021.